{"id":174878,"date":"2026-06-14T09:38:12","date_gmt":"2026-06-14T09:38:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch-fr\/174878\/"},"modified":"2026-06-14T09:38:12","modified_gmt":"2026-06-14T09:38:12","slug":"ces-deux-medicaments-contre-lobesite-sont-desormais-rembourses-en-france","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch-fr\/174878\/","title":{"rendered":"Ces deux m\u00e9dicaments contre l\u2019ob\u00e9sit\u00e9 sont d\u00e9sormais rembours\u00e9s en France"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">Traitement &#8211; Le Wegovy et Mounjaro seront rembours\u00e9s en France d\u00e8s lundi en tant que traitements anti-ob\u00e9sit\u00e9 mais dans un cadre tr\u00e8s contraint pour le moment<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Les <a href=\"https:\/\/www.20minutes.fr\/sante\/4226774-20260603-obesite-esperais-plus-utilisent-traitements-wegovy-mounjaro-bientot-partie-rembourses?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:traitements anti-ob\u00e9sit\u00e9;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;traitements anti-ob\u00e9sit\u00e9&quot;}\" class=\"link \">traitements anti-ob\u00e9sit\u00e9<\/a> Wegovy et Mounjaro ont rapidement conquis leur place \u00e0 l\u2019\u00e9chelle mondiale. En France, si leur remboursement par l\u2019<a href=\"https:\/\/www.20minutes.fr\/dossier\/assurance_maladie?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:Assurance maladie;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Assurance maladie&quot;}\" class=\"link \">Assurance maladie<\/a> d\u00e9bute lundi, les contraintes seront strictes.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Ces analogues du GLP-1, une classe de m\u00e9dicaments qui contr\u00f4le la glyc\u00e9mie et <a href=\"https:\/\/www.20minutes.fr\/tempo\/food\/4219008-20260418-metabolisme-lent-aliments-privilegier-favoriser-perte-poids?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:fait perdre du poids;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;fait perdre du poids&quot;}\" class=\"link \">fait perdre du poids<\/a>, sont d\u00e9sormais pris en charge \u00e0 65 % par l\u2019Assurance maladie pour les patients atteints d\u2019ob\u00e9sit\u00e9 massive sans comorbidit\u00e9 ou s\u00e9v\u00e8re avec comorbidit\u00e9.<\/p>\n<p>Les prix seront d\u00e9sromais fixes<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Seuls les m\u00e9decins des structures sp\u00e9cialis\u00e9es dans l\u2019ob\u00e9sit\u00e9, comme les centres sp\u00e9cialis\u00e9s de l\u2019ob\u00e9sit\u00e9 (CSO), peuvent \u00e9tablir la premi\u00e8re prescription de ces m\u00e9dicaments injectables. L\u2019ordonnance s\u00e9curis\u00e9e doit s\u2019accompagner d\u2019un formulaire de prise en charge.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Seul r\u00e9el changement attendu dans l\u2019imm\u00e9diat par Eric Myon, pharmacien \u00e0 Paris et secr\u00e9taire g\u00e9n\u00e9ral de l\u2019UNPF (Union National des Pharmacies de France) : \u00ab \u00e0 partir de lundi, tous les prix de ces GLP-1 seront identiques en France \u00bb, alors que jusque-l\u00e0 leurs prix variaient en fonction des officines.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">A court terme, le pharmacien ne s\u2019attend \u00ab pas \u00e0 une \u00e9volution de la demande \u00bb : \u00ab les m\u00e9decins ne vont pas pouvoir voir tous les patients voulus d\u2019ici \u00e0 l\u2019\u00e9t\u00e9 \u00bb et, selon lui, les autres patients d\u00e9j\u00e0 trait\u00e9s qui ne rentrent pas dans les crit\u00e8res, \u00ab vont continuer \u00e0 les acheter \u00bb hors prise en charge.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Un million de personnes seraient potentiellement \u00e9ligibles, mais le minist\u00e8re de la Sant\u00e9 estime que la r\u00e9alit\u00e9 sera probablement en dessou(&#8230;)<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\"><a href=\"https:\/\/www.20minutes.fr\/sante\/4228921-20260614-deux-medicaments-contre-obesite-desormais-rembourses-france?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=read_more_link&quot;\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:Lire la suite sur 20minutes;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Lire la suite sur 20minutes&quot;}\" class=\"link \">Lire la suite sur 20minutes<\/a><\/p>\n<p>\u00c0 lire aussi :<br \/><a href=\"https:\/\/www.20minutes.fr\/sante\/4226774-20260603-obesite-esperais-plus-utilisent-traitements-wegovy-mounjaro-bientot-partie-rembourses?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=related_content_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:Ob\u00e9sit\u00e9 : \u00ab Je n\u2019esp\u00e9rais m\u00eame plus \u00bb\u2026 Ils utilisent les traitements Wegovy ou Mounjaro, bient\u00f4t en partie rembours\u00e9s;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Ob\u00e9sit\u00e9 &quot;}\" class=\"link \">Ob\u00e9sit\u00e9 : \u00ab Je n\u2019esp\u00e9rais m\u00eame plus \u00bb\u2026 Ils utilisent les traitements Wegovy ou Mounjaro, bient\u00f4t en partie rembours\u00e9s<\/a><br \/><a href=\"https:\/\/www.20minutes.fr\/justice\/4221750-20260504-medicaments-wegovy-saxenda-sanctionnes-publicites-anti-obesite?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=related_content_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"elm:link;elmt:article_link;slk:Les m\u00e9dicaments Wegovy et Saxenda sanctionn\u00e9s pour des publicit\u00e9s anti-ob\u00e9sit\u00e9;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Les m\u00e9dicaments Wegovy et Saxenda sanctionn\u00e9s pour des publicit\u00e9s anti-ob\u00e9sit\u00e9&quot;}\" class=\"link \">Les m\u00e9dicaments Wegovy et Saxenda sanctionn\u00e9s pour des publicit\u00e9s anti-ob\u00e9sit\u00e9<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Traitement &#8211; Le Wegovy et Mounjaro seront rembours\u00e9s en France d\u00e8s lundi en tant que traitements anti-ob\u00e9sit\u00e9 mais&hellip;\n","protected":false},"author":2,"featured_media":174879,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[9],"tags":[30,83,17727,3251,41397,4943,84,23],"class_list":["post-174878","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sante","tag-france","tag-health","tag-lobesite","tag-medicaments","tag-ministere-de-la-sante","tag-prise-en-charge","tag-sante","tag-suisse"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch_fr\/116747796867913489","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/174878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/comments?post=174878"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/174878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media\/174879"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media?parent=174878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/categories?post=174878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/tags?post=174878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}